Watchlist

Watchlist
Advaxis, Inc. (ADXS)
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will release financial results for the fiscal year ended October 31, 2017 on Wednesday, December 20, 2017…
3 Things In Biotech You Should Learn Today: December 13, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AbbVie spikes the ball at ASH 2017 Company: AbbVie ( ABBV ) and Roche ( RHHBY ) Therap…
Advaxis (ADXS) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
The following slide deck was published by Advaxis Inc. in conjunction with this Read more …
Advaxis to Present at the Jefferies 2017 London Healthcare Conference
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products,today announces that company management will participate in the Jefferies 2017 London Healthcare Conference taking place Novemb…
Your Daily Pharma Scoop: Timing Synergy Trade, Valeant's Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we …
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, has received approval for a $4.8 million tax credit from the New Jersey Economic Development Authoritys (NJEDA) New Jersey T…
Advaxis: So It's Panic, Then? Where This Thing Is Headed
So, Advaxis ( ADXS ). If you follow me, you know it's one of the few stocks I write about that I actually own. So I'll have that disclaimer out of the way immediately. In 2017, ADXS has gone through its first taste of validation with the presentation of GOG-0265 results back in March, but t…
Midday Gainers /Losers
Gainers: VISI +61% . PTIE +43% . SSKN +40% . USEG +31% . LTEA +18% . BGI +16% . RCON +16% . CONN +15% . TESS +15% . PII +15% . More news on: Volt Information Sciences, Inc., Pain Therapeutics, STRATA Skin Sciences, Inc, Stocks on the move, Read more …...
Daily Insider Ratings Round Up 10/12/17: GLPW, ADXS, KALV
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "…
Your Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA Approval
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of an SA Marketplace Interview: Bias on the Street against SGYP Today…
3 Things In Biotech You Should Learn Today: October 11, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Eli Lilly's abemaciclib fails a big test for lung cancer Company: Eli Lilly & Company…
Advaxis, Inc. (ADXS)